Cargando…

Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab

BACKGROUND: Rituximab (RTX) and ocrelizumab (OCR), B cell-depleting therapy targeting CD20 molecules, affect the humoral immune response after vaccination. How these therapies influence T-cell-mediated immune response against SARS-CoV-2 after immunization remains unclear. We aimed to evaluate the hu...

Descripción completa

Detalles Bibliográficos
Autores principales: Nytrova, Petra, Stastna, Dominika, Tesar, Adam, Menkyova, Ingrid, Posova, Helena, Koprivova, Helena, Mikulova, Veronika, Hrdy, Jiri, Smela, Gabriela, Horakova, Dana, Rysankova, Irena, Doleckova, Kristyna, Tyblova, Michaela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312310/
https://www.ncbi.nlm.nih.gov/pubmed/37398654
http://dx.doi.org/10.3389/fimmu.2023.1149629